The PCAC meeting, including testimony from key opinion leaders, physicians, and pharmacists, did not create these expectations
May support healthy metabolic processes including fat metabolism, energy expenditure, and body composition when combined with proper lifestyle factors
Some people regain weight if lifestyle changes are not maintained after stopping treatment
But theres a catch the effect only lasts while you keep taking it
Is it too early to start
The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)